Subtle Medical Expands AI Imaging Platform with FDA Clearance for CT Enhancement Software

Subtle Medical has received FDA clearance for SubtleHD(CT), an AI-powered software platform designed to improve computed tomography (CT) image quality by reducing noise and enhancing low-contrast detectability.

The clearance marks the company's expansion beyond PET and MRI imaging enhancement, extending its AI imaging platform into one of the most widely used diagnostic modalities in healthcare.

The announcement follows closely behind the company's $33m Series C financing round and highlights growing momentum behind AI-driven workflow optimisation in medical imaging.

Bringing AI Enhancement to Existing CT Infrastructure

SubtleHD(CT) has been developed as a software-as-a-medical-device (SaMD) that integrates directly into existing radiology workflows.

Rather than requiring new imaging hardware, the platform is designed to improve image quality across a broad range of scanner fleets, including older CT systems that remain heavily utilised in hospitals and imaging centres.

This approach reflects a growing trend across healthcare technology: using software to extend the useful life and performance of existing infrastructure rather than relying solely on capital-intensive equipment upgrades.

For providers facing budget pressures and increasing imaging demand, AI enhancement tools offer a potential route to improving diagnostic quality without large-scale hardware replacement programmes.

AI's Growing Role in Radiology Workflows

SubtleHD(CT) joins a broader portfolio of AI imaging products already commercialised by Subtle Medical.

The company's platform now includes:

• SubtlePET for PET image enhancement and workflow acceleration

• SubtleHD(MR) for MRI image quality improvement

• SubtleALIGN for automated MRI positioning and alignment

• SubtleSYNTH for generating MRI contrasts from existing image sequences
  

Together, these products form part of Subtle's vendor-neutral AI Imaging Hub, designed to operate across multiple scanner manufacturers and healthcare environments.

The strategy positions AI not as a standalone diagnostic tool, but as a workflow layer capable of improving image acquisition, standardisation and efficiency across the imaging pathway.

Addressing Capacity Challenges in Medical Imaging

The clearance also arrives against a backdrop of growing workforce pressure in radiology.

Healthcare systems globally continue to face rising imaging demand while struggling to recruit sufficient numbers of radiologists and imaging specialists.

According to projections from the Association of American Medical Colleges (AAMC), the United States could face a radiologist shortfall approaching 42,000 professionals by 2036.

As a result, AI tools that reduce repeat scans, improve image consistency and streamline workflow efficiency are increasingly being viewed as operational necessities rather than experimental technologies.

Funding and Leadership Momentum

The FDA clearance follows Subtle Medical's recently completed $33m Series C financing round, which the company plans to use to accelerate product development and global commercial expansion.

The financing also coincided with the appointment of new CEO Ohad Arazi, an experienced healthcare technology executive whose previous leadership roles have included positions at Change Healthcare, Zebra Medical Vision and Clarius Mobile Health.

The combination of fresh capital, new leadership and regulatory momentum positions the company for broader adoption across imaging markets.

Why This Matters

SubtleHD(CT) reflects a broader shift in healthcare AI adoption. Rather than replacing clinicians, many of the most commercially successful AI applications are focused on improving workflow efficiency, image quality and operational capacity within existing clinical environments.

Medical imaging has emerged as one of the clearest examples of this trend, where AI can help healthcare systems manage growing demand while maximising the value of existing infrastructure and workforce resources.

Summary

The FDA clearance of SubtleHD(CT) expands Subtle Medical's AI imaging platform into CT diagnostics, adding image enhancement capabilities to one of healthcare's most widely used imaging modalities.

More broadly, the approval highlights how AI adoption in medical imaging is increasingly centred on workflow optimisation, infrastructure efficiency and clinician support as healthcare systems confront rising demand and growing workforce shortages.

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com